David Cachia

Dr. David Cachia

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2015 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
DCDavid Cachia
David Cachia
CKCarlos Kamiya-Matsuoka
Carlos Kamiya-Matsuoka
JMJacob Mandel
Jacob Mandel
AOAdriana Olar
Adriana Olar
MCMatthew D. Cykowski
Matthew D. Cykowski
JGJohn F. De Groot
John F. De Groot

6 April 2020 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
ADArabinda Das
Arabinda Das
MAM. Alshareef
M. Alshareef
JSJ. L. Martinez Santos
J. L. Martinez Santos
GPG. B. F. Porto
G. B. F. Porto
DMD. G. McDonald
D. G. McDonald
DCDavid Cachia
David Cachia

1 November 2018 in Oncolytic Virotherapy
Verified
Journal Article
Open access
PDF file
CBChase Burton
Chase Burton
ADArabinda Das
Arabinda Das
DMDaniel McDonald
Daniel McDonald
WIWilliam A. Vandergrift Iii
William A. Vandergrift Iii
SPSunil J. Patel
Sunil J. Patel
EBEric Bartee
Eric Bartee
Background: Glioblastoma multiforme (GBM) is an aggressive form of brain cancer which is associated with poor prognosis. A variety of oncolytic viruses have previously shown positive efficacy against GBM, potentially offering new treatment options for patients. One such oncolytic virus is Myxoma virus (MYXV), a rabbit-specific poxvirus that has been shown to be efficacious against a variety of tumor models including GBM. Purpose: The purpose of this study was to test the efficacy of MYXV combined with current treatment regimens for GBM in both established cell lines as well as patient biopsy samples. Materials and methods: U118 gliobastoma cell lines were treated under various standard of care combinations (untreated, radiation and chemotherapeutic) prior to infection with MYXV. Infection was then monitored for differences in rate of infection, titer and rate of spread. Cellular death was measured by MTT assay and Caspase-3 colorimetric assay. Patient biopsies were harvested and treated under similar treatment conditions. Results: The addition of GBM standard of care to MYXV infection resulted in an increased rate of spread compared to single treatment with either radiation or chemotherapeutic alone. SOC did not alter viral replication or infection rates. Similar effects were seen in ex vivo patient biopsies. Cellular viability was significantly decreased with the combination therapy of SOC and MYXV infection compared to any other treatment outcome. Caspase-3 activity was also significantly increased in samples treated with combination therapy when compared to any other treatment combination. Conclusion: Our results show that the combination of MYXV with current SOC results in both increased killing of GBM cells compared to either treatment regime alone as well as increased spread of MYXV infection. These findings lay the foundation for future in vivo studies on combining MYXV with GBM SOC.

1 May 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
RHRebecca Harrison
Rebecca Harrison
MAMark D. Anderson
Mark D. Anderson
DCDavid Cachia
David Cachia
CKCarlos Kamiya-Matsuoka
Carlos Kamiya-Matsuoka
SWShiao-Pei Weathers
Shiao-Pei Weathers
JGJohn F. de Groot
John F. de Groot

12 July 2017 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
DCDavid Cachia
David Cachia
NENabil A. Elshafeey
Nabil A. Elshafeey
CKCarlos Kamiya-Matsuoka
Carlos Kamiya-Matsuoka
MHMasumeh Hatami
Masumeh Hatami
KAKristin Alfaro
Kristin Alfaro
JDJohn F. DeGroot
John F. DeGroot

24 July 2018 in Neuro-Oncology Practice
Verified
Journal Article
Closed access
PDF file
DCDavid Cachia
David Cachia
DJDerek R Johnson
Derek R Johnson
TKTimothy J Kaufmann
Timothy J Kaufmann
SLStephen Lowe
Stephen Lowe
SASamuel Andersen
Samuel Andersen
MGMark R Gilbert
Mark R Gilbert
Ependymomas are rare primary central nervous system (CNS) tumors in adults. They occur most commonly in the spinal cord, and have classically been graded histologically into World Health Organization (WHO) grades I, II, or III based on the level of anaplasia. Recent data are showing that genetic heterogeneity occurs within the same histological subgroup and that ependymomas arising from different CNS locations have different molecular signatures. This has renewed interest in developing targeting therapies based on molecular profiles especially given the variable outcomes with radiation and the poor results with cytotoxic agents. In this paper, we present the case of a 46-year-old woman with a classic presentation of spinal cord ependymoma and discuss the current histopathological and molecular classification for ependymomas as well as current guidelines for patient management.